New Drug Combination Could Prevent Head and Neck Cancer in High-risk Patients
A new drug combination shows promise in reducing the risk for patients with advanced oral precancerous lesions to develop squamous cell carcinoma of the head and neck. The results of the study, which included preclinical and clinical analyses, were published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
“Squamous cell carcinoma of the head and neck…is the most common type of head and neck cancer,” said Dong Moon Shin, MD, Professor of Hematology, Medical Oncology, and Otolaryngology at Emory University School of Medicine, and Director of the Cancer Chemoprevention Program at Winship Cancer Institute at Emory University in Atlanta. “The survival rate for patients with [this disease] is very poor. An effective prevention approach is desperately needed, especially since we can identify patients who are at extremely high risk: those with advanced oral precancerous lesions.”
Based on prior research suggesting a role for epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) in promoting squamous cell carcinoma of the head and neck, Dr. Shin and colleagues believed combining an EGFR inhibitor and a COX-2 inhibitor could provide an effective chemopreventive approach.
They found that the combination of the EGFR inhibitor erlotinib (Tarceva) and the COX-2 inhibitor celecoxib (Celebrex) was more effective for inhibiting the growth of human squamous cell carcinoma of the head and neck cell lines compared with either drug alone. In addition, treating mice with the drug combination prior to transplanting them with human cells more effectively suppressed cancer cell growth than did pretreating the mice with either drug alone.
Phase I Trial
Based on these preclinical analyses, the researchers initiated a phase I chemoprevention trial. Eleven patients with advanced oral precancerous lesions were assigned to treatment with erlotinib and celecoxib. Tissue samples from the patients were obtained and evaluated pathologically at 3, 6, and 12 months after therapy initiation. Biopsies at baseline and follow-up were available for seven patients.
Pathologic examination of the biopsies indicated that three of the seven patients had a complete pathologic response; that is, there was no longer evidence of the precancerous lesions in the follow-up biopsy sample. Among the other patients, two had a partial pathologic response and two had progressive disease.
“Finding that this drug combination caused some advanced premalignant lesions to completely disappear was great news,” said Dr. Shin. “Advanced premalignant lesions rarely regress, so our data are proof-of-principle that a combination chemopreventive strategy with molecularly targeted agents is possible.”
Several patients dropped out of the trial because of severe adverse side effects, according to Dr. Shin. “Prevention is not achieved through short-term treatment,” he said. “So, we need to investigate the safety and toxicity of this combination further before planning a large-scale trial. We are also looking to combination therapies using less toxic or nontoxic agents, such as natural compounds.”
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
